Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 3 (HACD3) is an endoplasmic reticulum-associated enzyme responsible for the dehydration of 3-hydroxyacyl-CoA to trans-2,3-enoyl-CoA, constituting the third step in the elongation cycle of very-long-chain fatty acids (VLCFAs). This process is vital for generating membrane lipids and lipid mediators of various chain lengths, impacting numerous physiological processes. HACD3 is also implicated in certain signaling pathways, notably Rac1 signaling and insulin receptor function. Mutations or dysregulation of HACD3 have been associated with disorders involving VLCFA metabolism, such as developmental and epileptic encephalopathy and Fiedler's myocarditis[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase 3 (HACD3).